- Opinion
- [Reporter’s View]Trust is essential to prevent a MERS II
- by Lee, Hye-Kyung Feb 5, 2020 02:22am
- As the fourth confirmed person in China's Wuhan Pneumonia (2019-nCoV Infection) emerges, there is growing concern over whether outbreak of the Middle East Respiratory Syndrome (MERS) that occurred in 2015 could be reproduced. Beyond the concerns, people who have experienced the MERS crisis, as well as nursing institutions such as hospitals, c
- Policy
- Insurance not covered if Revlimid prescribed multiple up
- by Lee, Hye-Kyung Feb 4, 2020 08:16pm
- Insurance will not be covered if Revlimid’s lower dose such as 5mg in multiples by Celgene is prescribed instead of Revlimid 10mg, 15mg, 20mg, or 25mg. Reimbursed price of Revlimid 25mg is &8361;101,768, whereas Revlimid 2.5mg, 1/10 dose of Revlimid 25mg, is &8361;53,904. If 10 tablets of Revlimid 2.5mg is prescribed instead of 1 table
- Company
- DC passes second PARP option Zejula fast with reimbursement
- by Eo, Yun-Ho Feb 4, 2020 06:32am
- After winning National Health Insurance reimbursement, anticancer treatment Zejula has been quick to get listed on general hospital prescription list. According to the pharmaceutical industry on Jan. 4, Takeda Pharmaceuticals Korea’s Zejula (niraparib) has been passed by drug committees of 16 major hospitals nationwide, including Seoul
- Policy
- Patent litigation to decide prospects of Olostar generic
- by Lee, Tak-Sun Feb 4, 2020 06:32am
- For the first time, a generic drug with same active ingredient (olmesartan medoxomil, rosuvastatin calcium) contained in Daewoong Pharmaceutical’s blockbuster co-morbid hypertension and dyslipidemia treatment, Olostar, has applied for approval. Presumably, the generic manufacturer would be either Kolmar Korea or a CMO as Kolmar Korea’s
- Company
- Salespersons, working at home due to Wuhan virus
- by Kim, Jin-Gu Feb 4, 2020 06:31am
- Hospitals and pharmaceutical companies took action in the aftermath of the new corona virus (Wuhan pneumonia). It is advisable to refrain from entering the hospital for the sales person for a while until the situation calms down. Some pharmaceutical companies have even started working full-time at home. According to the pharmaceutical i
- Company
- Bayer to withdraw Levitra from Korean market
- by Kim, Jin-Gu Feb 4, 2020 06:31am
- Bayer Korea has decided to withdraw Levitra (vardenafil) from Korean market and leave Chong Kun Dang Pharmaceutical’s Yaila as the only erectile dysfunction treatment in Korea with vardenafil. Bayer Korea has notified respective drug distributing vendors that the supply of Levitra would be suspended from coming April. Superficially,
- Policy
- The HIRA approved 10 of 12 cases in Spinraza
- by Lee, Hye-Kyung Feb 4, 2020 06:31am
- Ten out of 12 applications for the 'Spinraza' reimbursement, which has a maximum insurance price of &8361;92.3 million, were approved. One case was failed, and one case was withheld due to a request for supplementary data. The HIRA (Director Seung-Taek Kim) released result of deliberation example on the website on the 31st including ▲ Immun
- Policy
- Value framework research explains why we need it
- by Lee, Hye-Kyung Feb 3, 2020 06:24am
- Experts claim value framework criteria and evidence fitting to Korean circumstances are needed to justify limited National Health Insurance (NHI) finance granting reimbursement on high-cost anticancer treatment with clinical uncertainty. The argument is that new value framework scales are needed for a new high-cost anticancer treatment with
- Policy
- 6-hour test kit targeting 2019-nCoV developed in Korea
- by Lee, Tak-Sun Feb 3, 2020 06:24am
- A laboratory test kit to confirm the 2019 novel coronavirus infection in six hours has been co-developed by a government body and private entity. From Jan. 31, the new test kit would used by Korea Centers for Disease Control and Prevention (KCDC) and Government Research Institute of Public Health and Environment to test suspected cases, and
- Opinion
- [Reporter’s view]Dilemma of salesperson suicide & reporting
- by Eo, Yun-Ho Feb 3, 2020 06:23am
- Sad things happen constantly. In the past year, four salespeople who worked for a multinational pharmaceutical company took their own lives. This is the minimum number known and confirmed. The circumstances of the company and the extreme choices are different. However, the common point was that the reason for suicide was 'the company they
